Hematopoietic cell transplantation (HCT) is an effective therapy for a broad range of hematological malignances and represents the first successful, widely applied cellular therapy for cancer. The mechanisms of improved outcomes are focused on hematopoietic and immunological engraftment from the donor to the recipient, resulting in graft vs tumor effects and immunological reconstitution. However, several major challenges remain, including immunological recognition and attack of the host termed graft vs host disease (GVHD), immunological incompetence resulting in frequent opportunistic infections, reactivation of endogenous viruses and disease relapse. We have made excellent progress in the prior funding period as detailed in the application. The overall goals of our Program Project Grant are to develop a more robust fundamental understanding of transplantation biology and address the major challenges of HCT including GVHD, disease relapse and immune reconstitution. We will tackle these major challenges through innovative animal modeling, comprehensive biological and molecular analysis, novel imaging of animal and human subjects and biologically focused translational clinical trials. In addition, we will explore the biology of key cellular populations including Treg, iNKT, TR1, CD8 memory and CAR T cells. Our Program involves 5 interactive Projects focusing on the biology and prevention of GVHD through an enhanced understanding of cellular imaging and immune regulation (Projects 1 and 2), prevention and treatment of disease relapse with memory CD8+ T cells and vaccination strategies (Project 3), improved function and efficacy of CAR T cells (Project 4) and monoclonal antibody based strategies (Project 5). These Projects are supported by three Cores (Administration and Clinical Trial Coordination, Biostatistics and Data Management and Cell Processing and Immune Monitoring). Through our interactive Program Project, we will gain novel insights into the biology of hematopoietic cell transplantation and develop innovative strategies to improve outcomes for patients with hematological malignancies. The knowledge gained has profound implications for cancer and transplantation biology and also for the treatment of patients with a broad range of immunological conditions such as autoimmune disorders and transplantation of solid organs.

Public Health Relevance

Overall Program Project Grant: Project Narrative Our goals through this highly interactive Program Project Grant are to develop a more fundamental understanding of the biology of hematopoietic stem cells, immune regulatory mechanisms and cancer treating approaches to better outcomes for patients with advanced hematological cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA049605-29A1
Application #
9793128
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Song, Min-Kyung H
Project Start
1997-05-01
Project End
2024-08-31
Budget Start
2019-09-16
Budget End
2020-08-31
Support Year
29
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Muffly, Lori; Sheehan, Kevin; Armstrong, Randall et al. (2018) Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv 2:681-690
Tavallaee, Mahkam; Steiner, David F; Zehnder, James L et al. (2018) Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol :
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Xu, Lian; Hunter, Zachary R; Tsakmaklis, Nicholas et al. (2016) Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol 172:735-44
Hinds, David A; Barnholt, Kimberly E; Mesa, Ruben A et al. (2016) Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 128:1121-8

Showing the most recent 10 out of 307 publications